Important effect of food on the bioavailability of oral testosterone undecanoate

Pharmacotherapy

Volumn 23, Issue 3, 2003, Pages 319-325

  Bagchus, Wilma M ^a   Hust, Rita ^c   Maris, Frans ^b   Schnabel, Peter G ^b   Houwing, Natalie S ^b  

^a NV ORGANON   (Netherlands)

^b Organon ^*  (Netherlands)

^c FOCUS Clinical Drug Development GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; TESTOSTERONE; TESTOSTERONE UNDECANOATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; FEMALE; FOOD DRUG INTERACTION; GAS CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MASS SPECTROMETRY; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; AGED; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; FASTING; FEMALE; FOOD; HUMANS; INTESTINAL ABSORPTION; MENOPAUSE; MIDDLE AGED; TESTOSTERONE;

EID: 0037370043     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.3.319.32104     Document Type: Article

References (8)

1. Geurts TBP, Coelingh Bennink HJT. Testosterone replacement therapy: testosterone undecanoate (Andriol). J Urol Urogenakol 2000: special edition;24-35.
2. Charman WN, Porter CJH. Lipophilic prodrugs designed for intestinal lymphatic transport. Adv Drug Deliv Rev 1996;19:149-69.
3. Noguchi T, Charman WN, Stella VJ. The effect of drug lipophilicity and lipid vehicles on the lymphatic absorption of various testosterone esters. Int J Pharm 1985;24:173-84.
4. Horst HJ, Höltje WJ, Dennis M, Coert A, Geelen J, Voigt KD. Lymphatic absorption and metabolism of orally administered testosterone undecanoate in man. Klin Wschr 1976;54:875-9.
5. Hirschhäuser C, Hopkinson CRN, Sturm G, Coert A. Testosterone undecanoate: a new orally active androgen. Acta Endocrinol 1975;80:179-87.
6. Khoo S-M, Edwards GA, Porter CJH, Charman WN. A conscious dog model for assessing the absorption, enterocytebased metabolism and intestinal lymphatic transport of halofantrine. J Pharm Sci 2001;90:1599-607.
7. Frey H, Aakvaag A, Saanum D, Falch J. Bioavailability of oral testosterone in males. Eur J Clin Pharmacol 1979;16:345-9.
8. Cantril JA, Dewis P, Large DM, Newman M, Anderson DC. Which testosterone replacement therapy? Clin Endocrinol 1984;21:97-107.